Patents by Inventor Hans-Peter Buchstaller

Hans-Peter Buchstaller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210002278
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 7, 2021
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter BUCHSTALLER
  • Patent number: 10829489
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: November 10, 2020
    Assignee: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Publication number: 20200253949
    Abstract: Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Application
    Filed: March 27, 2017
    Publication date: August 13, 2020
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter BUCHSTALLER
  • Publication number: 20200069690
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2019
    Publication date: March 5, 2020
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Publication number: 20200062756
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Application
    Filed: October 29, 2019
    Publication date: February 27, 2020
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter BUCHSTALLER
  • Patent number: 10570116
    Abstract: Compounds of the formula I in which Z, W, Q, R and Y have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: February 25, 2020
    Assignee: Merck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dieter Dorsch
  • Patent number: 10526325
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: January 7, 2020
    Assignee: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Patent number: 10428024
    Abstract: Compounds of the formula I in which X, Y, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Grant
    Filed: April 25, 2017
    Date of Patent: October 1, 2019
    Assignee: MERCK PATENT GMBH
    Inventor: Hans-Peter Buchstaller
  • Publication number: 20190256499
    Abstract: Substituted quinoxaline derivatives are useful for the prevention and/or treatment of medical conditions known as hyperproliferative diseases. The compounds are also useful for medical conditions that are affected by inhibiting 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB). Further, the compounds are useful for the prevention and/or treatment of cancer.
    Type: Application
    Filed: November 6, 2017
    Publication date: August 22, 2019
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Patent number: 10383874
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: August 20, 2019
    Assignee: Merk Patent GMBH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Publication number: 20190142833
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: November 13, 2018
    Publication date: May 16, 2019
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Publication number: 20190135753
    Abstract: Compounds of the formula I in which X, Y, R1 and R2 have the meanings indicated in claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Application
    Filed: April 25, 2017
    Publication date: May 9, 2019
    Applicant: MERCK PATENT GMBH
    Inventor: Hans-Peter BUCHSTALLER
  • Publication number: 20190092751
    Abstract: Compounds of the formula I in which Z, W, Q, R and Y have the meanings indicated in claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Application
    Filed: October 7, 2016
    Publication date: March 28, 2019
    Applicant: Merck Patent GmbH
    Inventors: Hans-Peter BUCHSTALLER, Dieter DORSCH
  • Publication number: 20190010151
    Abstract: Compounds of the formula Ia or of the formula Ib in which X, Y, R1 and R2 have the meanings indicated in claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.
    Type: Application
    Filed: June 30, 2016
    Publication date: January 10, 2019
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter BUCHSTALLER
  • Patent number: 10172859
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: January 8, 2019
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Patent number: 9901577
    Abstract: Compounds of the formula I in which R1-R3 and Z have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: February 27, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Hans-Peter Buchstaller
  • Patent number: 9809598
    Abstract: Compounds of the formula I in which W, X and Y have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: November 7, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Dieter Dorsch
  • Publication number: 20170290836
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitisation of cancer cells to anticancer agents and/or ionising radiation.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 12, 2017
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Patent number: 9770446
    Abstract: Compounds of the formula I in which R1-R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 26, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Hans-Peter Buchstaller, Dieter Dorsch
  • Patent number: 9751842
    Abstract: Compounds of the formula I in which R1, X and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: September 5, 2017
    Assignee: Marck Patent GmbH
    Inventors: Hans-Peter Buchstaller, Dieter Dorsch, Christina Esdar, Birgitta Leuthner